FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number    

 
 
CIBMTR Recipient ID:    

 
 
Today's Date: __ __ __ __ - __ __- __ __  

 
 
Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HSCT type (check all that apply): 

 
  

gfedcb
Autologous

 
 

  
gfedcb

Allogeneic, unrelated

 
 

  
gfedcb

Allogeneic, related

 
 

  
gfedcb

Syngeneic (identical twin)

 

Product type (check all that apply): 

 
  

gfedcb
Marrow

 
 

  
gfedcb

PBSC

 
 

  
gfedcb

Cord blood

 
 

  
gfedcb

Other product

 
 
Specify:    

 
 

Visit:

  
 nmlkji

100 day  
 nmlkji

6 months  
 nmlkji

1 year  
 nmlkji

2 years  
 nmlkji

> 2 years,  

 
 
Specify:    

 
1  Compared to the disease status prior to the preparative regimen, what was the best response to HSCT since the date of the last report? (Include response to any planned post-HSCT 

surgical resection or irradiation.) 

    
 nmlkji

continued complete response (CCR) - continued absence of all disease after a complete reponse from the pre-HSCT disease status  

 nmlkji
complete reponse (CR) - complete disappearance of all sites of known disease for > 4 weeks  

 nmlkji
complete response undetermined (CRU) - complete response with persistence of radiographic enhancing abnormalities of unknown significance  

 nmlkji
partial response (PR) - ≥50% reduction in greatest diameter of all sites of known disease, and no new sites of disease for > 4 weeks  

 nmlkji
no response (NR) - <50% reduction in greatest diameter of any known sites of disease, and no new sites of disease for 4 weeks  

 nmlkji
progressive disease (PD)- increase in size of any site of know disease, or any new sites of disease  

 nmlkji
Not assessed  

  
 
2  Date best response first began: __ __ __ __ - __ __- __ __  

 
  

gfedcb
date for the best response was previously reported

 
 

3  Has the disease relapsed or progressed since the date of the last report?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  
 
4  Date of progression / relapse: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date unknown

 
 

5  Allogeneic HSCTs only: Was there subsequent disease stability or regression without further therapy (so-called graft-versus-tumor effect)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  Key Fields 

Disease Assessment at the Time of Best Response to HSCT Questions: 1 - 2

  Relapse or Progression Post-HSCT Questions: 3 - 100

Form 2125 R2.0: Central Nervous System Tumor Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2125 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 6



 
 

6  Did this change in disease status qualify as a partial response or better if compared to a post-HSCT imaging study? (see page 1 for criteria to define partial response)

    
 nmlkji

yes  
 nmlkji

no  

  
 
7  Date of response: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date unknown

 

Specify site(s) of tumor recurrence / progression: 
 

8  Cerebrospinal fluid

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

9  Extraneural

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

10  Distant intracranial parenchymal

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

11  Intracranial leptomeningeal

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

12  Spinal leptomeningeal

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

13  Local primary site

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

14  Other site:

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
15  Specify site:    

 
16  Was planned treatment given per protocol since the date of the last report? (Include any maintenance therapy, but exclude any treatment for persistent, progressive or recurrent 

disease.) 

    
 nmlkji

yes  
 nmlkji

no  

 
 

17  Radiation Therapy:

    
 nmlkji

yes  
 nmlkji

no  

 
 
18  Date radiation therapy started: __ __ __ __ - __ __- __ __  

 
 
19  Date radiation therapy stopped: __ __ __ __ - __ __- __ __  

 

Specify radiation fields(s): 
 

20  Whole brain

    
 nmlkji

yes  
 nmlkji

no  

 
 
21  If yes, specify total dose:    cGy (rads) 

 
 

22  Local cranial

    
 nmlkji

yes  
 nmlkji

no  

 
 
23  If yes, specify total dose:    cGy (rads) 

 
 

24  Craniospinal

    
 nmlkji

yes  
 nmlkji

no  

 
 
25  If yes, specify total dose:    cGy (rads) 

 
 

26  Gamma knife / radiosurgery

    
 nmlkji

yes  
 nmlkji

no  

 
 
27  If yes, specify total dose:    cGy (rads) 

  Post-HSCT Planned Treatment for CNS Disease (1) Questions: 17 - 46 

Form 2125 R2.0: Central Nervous System Tumor Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2125 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 6



 
 

28  Interstitial irradiation/brachytherapy

    
 nmlkji

yes  
 nmlkji

no  

 
 
29  If yes, specify total dose:    cGy (rads) 

 
 

30  Radioactive instillation

    
 nmlkji

yes  
 nmlkji

no  

 
 
31  If yes, specify total dose:    cGy (rads) 

 
 

32  Local spinal

    
 nmlkji

yes  
 nmlkji

no  

 
 
33  If yes, specify total dose:    cGy (rads) 

 
 

34  Other radiation field

    
 nmlkji

yes  
 nmlkji

no  

 
 
35  If yes, specify total dose:    cGy (rads) 

 
 
36  Specify other radiation field    

 
 

37  Specify fractionation schedule:

    
 nmlkji

single  
 nmlkji

single daily  
 nmlkji

multiple daily  
 nmlkji

other schedule  

 
 

38  Surgical Biopsy / Resection:

    
 nmlkji

yes  
 nmlkji

no  

 
 
39  Date of surgery: __ __ __ __ - __ __- __ __  

 
 
40  Type of surgery:   

 
 
41  Size of residual tumor after surgery   

 
 

42  Was the extent of the surgical resection confirmed radiographically?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

43  Was any persistent, viable tumor detected?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
44  Best Response to Line of Therapy: (see definitions at question 1)   

 
 
45  If code 7, specify reason:   

 
 
46  Date the best response, including planned post-HSCT treatment, was achieved: __ __ __ __ - __ __- __ __  

 
 

47  Was treatment given for persistent, progressive or recurrent CNS disease since the dated of the last report?

    
 nmlkji

yes  
 nmlkji

no  

 
 

48  Systemic therapy:

    
 nmlkji

yes  
 nmlkji

no  

 
 
49  Date therapy started: __ __ __ __ - __ __- __ __  

 
 
50  Date therapy stopped: __ __ __ __ - __ __- __ __  

  
 
51  Number of cycles    

 
  

gfedcb
unknown / not applicable

 
 

52  bleomycin (BLM, Blenoxane)

    
 nmlkji

yes  
 nmlkji

no  

 
 

53  carboplatin (Paraplatin)

    
 nmlkji

yes  
 nmlkji

no  

  Post-HSCT Treatment for Persistent, Progressive, or Recurrent CNS Disease (1) Questions: 48 - 100 

Form 2125 R2.0: Central Nervous System Tumor Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2125 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 6



 
 

54  Cisplatin (Platinol, CDDP)

    
 nmlkji

yes  
 nmlkji

no  

 
 

55  Corticosteroids

    
 nmlkji

yes  
 nmlkji

no  

 
 

56  Cyclophosphamide (Cytoxan)

    
 nmlkji

yes  
 nmlkji

no  

 
 

57  Etoposide (VP-16, VePesid)

    
 nmlkji

yes  
 nmlkji

no  

 
 

58  ifosfamide (ifex)

    
 nmlkji

yes  
 nmlkji

no  

 
 

59  melphalan (L-PAM, Alkeran)

    
 nmlkji

yes  
 nmlkji

no  

 
 

60  methotrexate (MTX, Folex)

    
 nmlkji

yes  
 nmlkji

no  

 
 

61  nitrosourea (carmustine)

    
 nmlkji

yes  
 nmlkji

no  

 
 

62  procarbazine (Matulane)

    
 nmlkji

yes  
 nmlkji

no  

 
 

63  temozolomide (Temodar)

    
 nmlkji

yes  
 nmlkji

no  

 
 

64  thiotepa (Thioplex)

    
 nmlkji

yes  
 nmlkji

no  

 
 

65  topotecan (Hycamtin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

66  Vincristine (VCR, Oncovin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

67  other therapy

    
 nmlkji

yes  
 nmlkji

no  

 
 
68  Specify other therapy:    

 
 

69  Hematopoietic growth factor?

    
 nmlkji

yes  
 nmlkji

no  

 
 

70  # of chemo cycles used with:

    
 nmlkji

< 5  
 nmlkji

>= 5  
 nmlkji

Unknown  

 
 

71  Radiation Therapy:

    
 nmlkji

yes  
 nmlkji

no  

 
 
72  Date radiation therapy started: __ __ __ __ - __ __- __ __  

 
 
73  Date radiation therapy stopped: __ __ __ __ - __ __- __ __  

Form 2125 R2.0: Central Nervous System Tumor Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2125 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 6



 

Specify radiation field(s): 
 

74  Whole brain

    
 nmlkji

yes  
 nmlkji

no  

 
 
75  If yes, specify total dose:    cGy (rads) 

 
 

76  Local cranial

    
 nmlkji

yes  
 nmlkji

no  

 
 
77  If yes, specify total dose:    cGy (rads) 

 
 

78  Craniospinal

    
 nmlkji

yes  
 nmlkji

no  

 
 
79  If yes, specify total dose:    cGy (rads) 

 
 

80  Gamma knife / radiosurgery

    
 nmlkji

yes  
 nmlkji

no  

 
 
81  If yes, specify total dose:    cGy (rads) 

 
 

82  Interstitial irradiation / brachytherapy

    
 nmlkji

yes  
 nmlkji

no  

 
 
83  If yes, specify total dose:    cGy (rads) 

 
 

84  Radioactive instillation

    
 nmlkji

yes  
 nmlkji

no  

 
 
85  If yes, specify total dose:    cGy (rads) 

 
 

86  Local Spinal

    
 nmlkji

yes  
 nmlkji

no  

 
 
87  If yes, specify total dose:    cGy (rads) 

 
 

88  Other radiation field

    
 nmlkji

yes  
 nmlkji

no  

 
 
89  If yes, specify total dose:    cGy (rads) 

 
 
90  Specify other radiation field    

 
 

91  Specify fractionation schedule:

    
 nmlkji

single  
 nmlkji

single daily  
 nmlkji

multiple daily  
 nmlkji

other schedule  

 
 

92  Surgical Biopsy / Resection:

    
 nmlkji

yes  
 nmlkji

no  

 
 
93  Date of surgery: __ __ __ __ - __ __- __ __  

 
 
94  Type of surgery:   

 
 
95  Size of residual tumor after surgery (see codes at left)   

 
 

96  Was the extent of the surgical resection confirmed radiographically?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

97  Was any persistent, viable tumor detected?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
98  Best Response to Line of Therapy: (see definitions at question 1)   

 
 
99  Specify reason:   

 
 
100  Date the best response to post HSCT treatment was achieved: __ __ __ __ - __ __- __ __  

Form 2125 R2.0: Central Nervous System Tumor Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2125 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 6



 
 

101  What is the current disease status?

    
 nmlkji

complete remission  

 nmlkji
Not in complete remission  

 
 
102  Date the current disease status was established in this reporting period: __ __ __ __ - __ __- __ __  

  
 
First Name:    

 
Last Name:    

  
 
Phone number:    

 
Fax number:    

 
 
E-mail address:    

  Disease Status at the Time of Assessment for This Reporting Period Questions: 101 - 102

Form 2125 R2.0: Central Nervous System Tumor Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2125 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 6